Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature-Reference-Cited by-同舟云学术

Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature

Published:2013-03 Issue:3 Volume:5 Page:265-299
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Jain Archana¹,Singh Jasvinder A²³⁴

Affiliation:

1. Department of Medicine at School of Medicine, University of Alabama, Birmingham, AL, USA

2. Division of Epidemiology at School of Public Health, University of Alabama, Birmingham, AL, USA.

3. Medicine Service & Center for Surgical Medical Acute Care Research & Transitions, Birmingham VA Medical Center, Birmingham, AL, USA

4. Department of Orthopedic Surgery, Mayo Clinic College of Medicine, Rochester, MN, USA

Abstract

A focused review of the risk of harms of anti-TNF inhibitors in adult rheumatic diseases was performed. An increased risk of serious infections, tuberculosis and other opportunistic infections has been reported across various studies, with etanercept appearing to have a modestly better safety profile in terms of tuberculosis and opportunistic infections, and infliximab posing a higher risk of serious infections. Evidence suggests no increase in risk of cancer with anti-TNF biologics, but there is an increased risk of non-melanoma skin cancer. Elderly patients appear to be at increased risk of incident or worsening heart failure with anti-TNF biologic use.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt.13.10

Reference81 articles.

1. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis

2. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

3. Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome

4. TNF-α Antagonist Survival Rate in a Cohort of Rheumatoid Arthritis Patients Observed under Conditions of Standard Clinical Practice

5. Applying science in practice: the optimization of biological therapy in rheumatoid arthritis

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biologic Agents;Contemporary Dental Pharmacology;2024

2. Medications to Avoid When Treating Heart Failure;Managing Heart Failure in Primary Care: A Case Study Approach;2023

3. Novel potential XOD inhibitory peptides derived from Trachinotus ovatus: Isolation, identification and structure-function analysis;Food Bioscience;2022-06

4. Investigation of TNF-α and IL-6 Levels in the Sera of Non-Melanoma Skin Cancer Patients;Iranian Biomedical Journal;2021-03-01

5. Transient generalized proximal tubular dysfunction in an infant with a urinary tract infection: the effect of maternal infliximab therapy?;Case Reports in Perinatal Medicine;2021-01-01